论文部分内容阅读
目的探讨内生场热疗联合同步放化疗治疗晚期宫颈癌的疗效、不良反应以及对免疫功能的影响。方法选取60例中晚期宫颈癌患者,随机分为对照组和试验组,对照组患者给予同步放化疗;试验组患者在对照组的基础上给予内生场热疗,2次/周,共治疗8次,观察疗效、不良反应及免疫功能。结果 60例患者均完成治疗,对照组患者总有效率(CR+PR)为60.0%,试验组患者总有效率(CP+PR)为86.7%,两组差异有统计学意义(P<0.05);2年总生存率(OS)差异有统计学意义。不良反应主要为胃肠道反应和骨髓抑制,患者均可以耐受,其中试验组患者皮下脂肪硬结2例(6.67%),经常规治疗后痊愈。两组患者严重不良反应比较,差异无统计学意义(P>0.05)。试验组患者T淋巴细胞免疫功能及NK细胞免疫功能较对照组改善,差异有统计学意义(P<0.05)。结论内生场热疗联合同步放化疗能提高局部晚期宫颈癌的局部控制率,延长生存时间,改善患者免疫功能,不良反应轻,患者耐受性良好。
Objective To investigate the curative effect, adverse reactions and immune function of endometrial hyperthermia combined with concurrent chemoradiotherapy in the treatment of advanced cervical cancer. Methods Sixty patients with advanced cervical cancer were selected and randomly divided into control group and experimental group. Patients in control group were treated with concurrent chemoradiotherapy. Endogenous hyperthermia and 2 times / week were given to patients in test group on the basis of control group 8 times, observe the curative effect, adverse reaction and immune function. Results The total effective rate (CR + PR) in the control group was 60.0% and the total effective rate (CP + PR) in the experimental group was 86.7%. There was a significant difference between the two groups (P <0.05) ; 2-year overall survival (OS) difference was statistically significant. Adverse reactions were mainly gastrointestinal reactions and myelosuppression. All patients were tolerant. Among them, 2 cases (6.67%) of subcutaneous fat induration in the test group recovered after routine treatment. The two groups of patients with serious adverse reactions, the difference was not statistically significant (P> 0.05). The immune function of T lymphocytes and the immune function of NK cells in experimental group were better than those in control group, with statistical significance (P <0.05). Conclusions Endogenous hyperthermia combined with concurrent chemoradiotherapy can improve the local control rate of locally advanced cervical cancer, prolong the survival time and improve the immune function of patients with mild adverse reactions and good patient tolerance.